Advancing treatments for rare diseases Together

IRDiRC

02Jul

The foundation's CEO will serve as a core member of a strategic effort to advance progress in the field of Data Mining and Repurposing. The purpose of this Task Force is to gather global experts and identify opportunities for collaborations to speed up the exploitation of these new discovery tools.
The International Rare Diseases Research Consortium teams up researchers and organisations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases.
The Executive Committee of IRDiRC selected several topics for action which could be instrumental in accelerating R&D, among which, data mining and repurposing. As a key player in this field, EspeRare’s CEO, Caroline Kant has been invited to contribute to this “Data mining and repositioning Task Force”.

About IRDiRC
The International Rare Diseases Research Consortium (IRDiRC) was initiated by the European Commission and the US National Institutes for Health Research and launched in April 2011 to foster international collaboration in the rare diseases field. IRDiRC will team up researchers and organizations investing in rare diseases research in order to achieve two main objectives, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases by the year 2020.

For more click on the following link

16Apr

The EspeRare foundation has been presented by Sharon Terry at the International Rare Diseases Research Consortium (IRDiRC) in Dublin, on April 16th.

About IRDiRC: The International Rare Diseases Research Consortium (IRDiRC) was initiated by the European Commission and the US National Institutes for Health Research and launched in April 2011 to foster international collaboration in the rare diseases field. IRDiRC will team up researchers and organizations investing in rare diseases research in order to achieve two main objectives, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases by the year 2020.

View the programme

 View conference report